NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

ITOS

ITeos Therapeutics Inc

Jun 04 • 04:00PM ET

10.20

Dollar change +0.10
Percentage change 0.99	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM VXF IWN DFAT IBB SCHA VTWO DFAS PRFZ

Index	RUT	P/E	-	EPS (ttm)	-3.23	Insider Own	5.96%	Shs Outstand	38.27M	Perf Week	1.39%
Market Cap	390.40M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	116.90%	Shs Float	35.99M	Perf Month	41.96%
Income	-130.81M	PEG	-	EPS next Q	-0.89	Inst Own	113.04%	Short Float	7.62%	Perf Quarter	40.50%
Sales	35.00M	P/S	11.15	EPS this Y	15.74%	Inst Trans	23.27%	Short Ratio	2.35	Perf Half Y	19.30%
Book/sh	14.72	P/B	0.69	EPS next Y	44.03%	ROA	-20.30%	Short Interest	2.74M	Perf Year	-39.07%
Cash/sh	13.60	P/C	0.75	EPS next 5Y	3.89%	ROE	-23.68%	52W Range	4.80 - 18.13	Perf YTD	32.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.39%	ROI	-23.07%	52W High	-43.74%	Beta	1.51
Dividend TTM	-	Quick Ratio	14.13	Sales past 5Y	-	Gross Margin	96.41%	52W Low	112.50%	ATR (14)	0.56
Dividend Ex-Date	-	Current Ratio	14.13	EPS Y/Y TTM	14.60%	Oper. Margin	-435.19%	RSI (14)	74.86	Volatility	0.60% 5.16%
Employees	173	Debt/Eq	0.01	Sales Y/Y TTM	177.89%	Profit Margin	-373.75%	Recom	2.67	Target Price	12.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	24.92%	Payout	-	Rel Volume	0.59	Prev Close	10.10
Sales Surprise	-100.00%	EPS Surprise	15.79%	Sales Q/Q	-	Earnings	Apr 28 AMC	Avg Volume	1.17M	Price	10.20
SMA20	20.61%	SMA50	41.43%	SMA200	15.24%	Trades		Volume	691,769	Change	0.99%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
May-28-25	Downgrade	Wedbush	Outperform → Neutral	$12
May-14-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-14-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-13-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Show Previous Ratings

May-30-25 12:00PM	iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know (Zacks)
May-29-25 07:59AM	iTeos to shut down following $2bn GSK-partnered TIGIT asset failure (Pharmaceutical Technology)
May-28-25 08:30AM	iTeos Therapeutics Announces Its Intention to Wind Down Operations (GlobeNewswire) +17.94%
08:10AM	Cancer drugmaker iTeos to shut down (BioPharma Dive)
May-15-25 07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
06:00AM	Loading…
May-14-25 06:00AM	GSK and iTeos drop anti-TIGIT drug following trial failure (Clinical Trials Arena)
May-13-25 12:35PM	iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile (Benzinga) +13.44%
07:55AM	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
07:10AM	iTeos, GSK to shelve TIGIT drug after study setback (BioPharma Dive)
May-02-25 09:55AM	Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? (Zacks)
Apr-28-25 04:30PM	iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-25-25 04:35PM	iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) -5.44%
Mar-13-25 09:55AM	Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet (Zacks)
Mar-05-25 07:00AM	iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.99%
Jan-13-25 12:00PM	All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy (Zacks)
07:00AM	Loading…
Jan-10-25 07:00AM	iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-08-25 07:00AM	iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 07:20AM	iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo (TipRanks)
Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Loading…
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%
04:01PM	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Detheux Michel	Officer	Jun 04 '25	Proposed Sale	10.06	52,283	525,967		Jun 04 04:03 PM
DAVID L HALLAL	Director	Jun 04 '25	Proposed Sale	10.07	38,227	384,782		Jun 04 04:03 PM
EcoR1 Capital, LLC	10% Owner	May 15 '25	Buy	8.00	3,300,000	26,400,000	10,688,978	May 16 06:52 PM
EcoR1 Capital, LLC	10% Owner	May 14 '25	Buy	7.41	1,658,978	12,285,562	7,388,978	May 16 06:52 PM
GADICKE ANSBERT	Former 10% Owner	May 13 '25	Sale	8.06	1,031,931	8,317,364	3,452,797	May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:33 PM
MPM BioVentures 2014, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:32 PM
Van Hauwermeiren Timothy	Director	May 13 '25	Option Exercise	4.30	22,346	96,088	22,346	May 14 08:00 PM
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

Dollar change -0.05
Percentage change -3.68	%

HOWL Werewolf Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA BLUE BMRN EDIT RCKT SGMO CLLS ADVM SLDB

| Held by: VTI IWM VXF IWN VTWO IWO IWC RSSL VTWV VTWG

Index	RUT	P/E	-	EPS (ttm)	-1.64	Insider Own	26.20%	Shs Outstand	44.83M	Perf Week	7.38%
Market Cap	58.79M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	4.70%	Shs Float	33.12M	Perf Month	38.11%
Income	-72.41M	PEG	-	EPS next Q	-0.47	Inst Own	47.56%	Short Float	6.71%	Perf Quarter	5.65%
Sales	1.14M	P/S	51.57	EPS this Y	-6.03%	Inst Trans	-4.16%	Short Ratio	5.83	Perf Half Y	-34.50%
Book/sh	1.28	P/B	1.02	EPS next Y	9.45%	ROA	-50.84%	Short Interest	2.22M	Perf Year	-74.66%
Cash/sh	2.05	P/C	0.64	EPS next 5Y	-3.48%	ROE	-82.81%	52W Range	0.60 - 4.18	Perf YTD	-11.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.76%	ROI	-77.94%	52W High	-68.66%	Beta	0.67
Dividend TTM	-	Quick Ratio	8.09	Sales past 5Y	-	Gross Margin	-55.38%	52W Low	120.17%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	8.09	EPS Y/Y TTM	-50.02%	Oper. Margin	-6511.20%	RSI (14)	65.10	Volatility	8.20% 7.20%
Employees	46	Debt/Eq	0.65	Sales Y/Y TTM	-92.95%	Profit Margin	-6335.17%	Recom	1.00	Target Price	9.50
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	-3.67%	Payout	-	Rel Volume	1.24	Prev Close	1.36
Sales Surprise	-	EPS Surprise	-1.32%	Sales Q/Q	-100.00%	Earnings	May 08 BMO	Avg Volume	381.48K	Price	1.31
SMA20	18.07%	SMA50	36.53%	SMA200	-17.98%	Trades		Volume	471,941	Change	-3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform	$12
Aug-24-23	Initiated	Wedbush	Outperform	$9
Jun-06-23	Resumed	Jefferies	Buy	$11 → $12
Sep-10-21	Initiated	BofA Securities	Buy	$26
May-25-21	Initiated	SVB Leerink	Outperform	$29
May-25-21	Initiated	Jefferies	Buy	$22
May-25-21	Initiated	H.C. Wainwright	Buy	$32
May-25-21	Initiated	Evercore ISI	Outperform	$23

May-29-25 12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 (GlobeNewswire) -5.26%
May-13-25 08:00AM	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
May-08-25 07:00AM	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
05:10PM	Loading…
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 08:05AM	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer (GlobeNewswire) +8.37%
Mar-31-25 08:00AM	Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.61%
Mar-11-25 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-25 08:00AM	Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-24-25 07:30AM	Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors (GlobeNewswire)
Jan-14-25 08:35AM	Werewolf Therapeutics provides business update, highlights 2025 outlook (TipRanks)
08:00AM	Loading…
Jan-13-25 08:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire)
Nov-20-24 08:00AM	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference (GlobeNewswire)
Nov-07-24 09:02AM	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) -8.20%
09:00AM	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 08:00AM	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases (GlobeNewswire) -5.02%
Oct-20-24 06:04AM	Bank of America Predicts up to ~390% Surge for These 2 Strong Buy Stocks (TipRanks)
Oct-04-24 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.09%
Aug-08-24 08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.19%
07:05AM	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-25-24 07:00AM	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (GlobeNewswire) -10.34%
Jun-01-24 09:00AM	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire)
May-30-24 08:00AM	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.30%
May-23-24 05:00PM	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) +5.52% -5.43%
May-03-24 01:53PM	HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-24 10:05AM	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 08:00AM	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) +5.75%
Apr-15-24 12:00PM	All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy (Zacks) +17.06%
Apr-05-24 04:30PM	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) -9.12%
Apr-04-24 04:30PM	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire)
Mar-12-24 09:55AM	How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37% (Zacks)
Mar-07-24 02:52PM	HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:45AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 08:00AM	Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire)
Jan-08-24 07:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire)
Jan-04-24 04:05PM	Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors (GlobeNewswire) +20.69%
Nov-22-23 07:00AM	Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 04:25PM	Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 07:00AM	Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +47.44%
Oct-31-23 09:00AM	Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks) +6.49%
Sep-27-23 09:00AM	Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +11.00%
Sep-11-23 04:05PM	Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire)
Sep-05-23 04:05PM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 09:57AM	Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls (The Fly) +26.74%
Aug-13-23 08:04AM	Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
Aug-11-23 03:21PM	Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-23 06:10AM	Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$11m last week but private equity firms profited the most (Simply Wall St.) +5.90%
Jun-01-23 07:00AM	Werewolf Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +14.42%
May-11-23 08:35AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.88%
07:00AM	Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:00AM	Werewolf Therapeutics to Participate in May Investor Conferences (GlobeNewswire) +5.49%
Apr-19-23 10:00AM	Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research (GlobeNewswire)
Mar-23-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.24%
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-23 07:30AM	UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-15-23 07:30AM	Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-24-23 07:30AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 (GlobeNewswire) -13.77%
Feb-17-23 05:08AM	Investors in Werewolf Therapeutics (NASDAQ:HOWL) have unfortunately lost 53% over the last year (Simply Wall St.)
Feb-07-23 07:00AM	Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 05:16AM	Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) top owners are private equity firms with 42% stake, while31% is held by institutions (Simply Wall St.) +22.51%
Dec-12-22 10:22AM	Is Werewolf Therapeutics (NASDAQ:HOWL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +7.26%
Nov-10-22 09:00AM	Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE Molecule, at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 07:00AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors (GlobeNewswire) +19.57%
Aug-15-22 06:45AM	Shareholders in Werewolf Therapeutics (NASDAQ:HOWL) are in the red if they invested a year ago (Simply Wall St.)
Aug-11-22 07:00AM	Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +14.02%
Aug-03-22 07:00AM	Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Jul-05-22 07:54AM	We Think Werewolf Therapeutics (NASDAQ:HOWL) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-06-22 04:51PM	Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +21.22%
May-10-22 07:00AM	Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +10.95%
Apr-08-22 02:29PM	JAZZ Inks Deal With Werewolf to Add Oncology Candidate (Zacks)
01:00PM	Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE Molecules at AACR 2022 Annual Meeting (GlobeNewswire)
Apr-07-22 09:25AM	Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma (Benzinga) +23.47%
08:34AM	Jazz, Werewolf sign licensing deal worth up to $1.2 billion (MarketWatch)
07:00AM	Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN INDUKINE Molecule (PR Newswire)
Mar-24-22 07:00AM	Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-16-22 08:00AM	Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment (GlobeNewswire)
Mar-15-22 08:00AM	Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-08-22 08:00AM	Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-26-22 06:53AM	Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 08:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-14-21 04:01PM	Werewolf Therapeutics Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-01-21 08:00AM	Werewolf Therapeutics to Present Preclinical Data on INDUKINE Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.45%
Nov-10-21 07:00AM	Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Nov-08-21 08:03AM	Werewolf Therapeutics to Present at Upcoming Conferences in November 2021 (GlobeNewswire)
Oct-28-21 04:01PM	Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors (GlobeNewswire)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	May 12 '25	Buy	0.86	320,913	275,985	6,021,969	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 14 '25	Buy	0.98	162,539	159,288	6,237,482	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 13 '25	Buy	0.98	52,974	51,915	6,074,943	May 14 06:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Mar 27 '25	Sale	1.05	1,963	2,061	3,208,793	Apr 30 04:17 PM
EVNIN LUKE	Director	Mar 27 '25	Sale	1.05	2,425	2,546	4,309,860	Apr 30 04:09 PM
GADICKE ANSBERT	10% Owner	Mar 27 '25	Sale	1.05	4,386	4,605	6,718,670	Apr 30 04:08 PM

ITOS

ITeos Therapeutics Inc

HOWL

Werewolf Therapeutics Inc

Upgrade your FINVIZ experience